FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

RXi licences ovarian cancer vax

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Worcester, MA-based RXi Pharmaceuticals has licensed an ovarian cancer vaccine from The University of Texas MD Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military Medicine. The vaccine, which is designed to prevent the recurrence of endometrial adenocarcinomas, as well as ovarian and other gynecological cancers, targets folate binding protein-E39. FBP is overexpressed in ovarian and aggressive endometrial cancers, as well as breast, lung, colorectal and renal cell carcinomas. Phase I trials will begin later this year. Release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about ovarian cancer vaccine   RXi Pharmaceuticals